Lobaplatin

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

• * death

• * life-threatening

• * hospitalisation

• * disability

• * congenital anomaly

• * other medically important event

A 51-year-old man developed nausea, oral mucositis, fatigue, anorexia, neutropenia, hyponatraemia and aggravation of pre-existing anaemia during treatment with lobaplatin for nasopharyngeal non-keratinising squamous cell carcinoma.

The man presented in the hospital located in Wuhan, China with complaints of bloody sucked-back snot and decreased hearing ability on 11 December 2019. He had a history of hypophysoma resection in 2003 and chronic kidney disease since 2010. He was diagnosed with nasopharyngeal non-keratinising squamous cell carcinoma (cT3N1M0). Additionally, he had hypoalbuminaemia (Grade 1), anaemia (Grade 1) and hypothyroidism. On 19 December 2020, he started receiving lobaplatin 35 mg/m ² on day 1 and day 22 till 09 January 2020 [route not stated]. From 23 December 2019, he received radiation therapy till 07 February 2020. During the treatment, he developed adverse effects including nausea (Grade 1), oral mucositis (Grade 1–2), fatigue (Grade 1), anorexia (Grade 1–3), neutropenia (Grade 2), hyponatraemia (Grade 1–4) and aggravation of pre-existing anaemia (Grade 1–2) [duration of treatment to reactions onsets not stated]. He wanted to quit the therapy due to pain from mucositis (Mucosal hyperaemia and ulcer) and weight loss of 7.5kg due to anorexia. However, with psychological support, he completed the treatment and all the adverse effects were improved or resolved after unspecified symptomatic treatment.

On 26 January 2020, the man developed fever, mild dysphoria and fatigue. Subsequently, he was diagnosed with coronavirus disease (COVID-19) and started receiving off-label treatment with oseltamivir, ribavirin, Lianhua-Qingwen, thymopentin immune-globulin [immune globulin Ph4], recombinant human interferon-alpha-1B [interferon-a1B] and supportive nutrition therapy. Eventually, his symptoms improved partly or totally with resolution of viral pneumonia on 26 February 2020. During the admission, his lymphocyte counts decreased, which was highly correlated with the change of disease. On 28 February 2020, he was discharged and quarantined for 14 days in community-designated accommodation for medical observation. His subsequent COVID-19 tests were negative. On 12 May 2020, his oncological evaluation revealed clinically complete response to the radiochemotherapy. In most recent follow up on 09 June 2020, he was in good condition, gained 6kg weight and had no relapse of the symptoms.